<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490100</url>
  </required_header>
  <id_info>
    <org_study_id>070171</org_study_id>
    <secondary_id>07-I-0171</secondary_id>
    <nct_id>NCT00490100</nct_id>
  </id_info>
  <brief_title>Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1</brief_title>
  <official_title>Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency (XSCID): A Phase 2 Study Assessing Safety and Clinical Response to Treatment With Insulin-like Growth Factor-1 (IGF-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of insulin-like growth factor-1 (IGF-1)
      to treat patients with X-linked severe combined immunodeficiency (XSCID). Those who have
      XSCID lack white blood cells that protect their bodies from invasion by all types of germs.
      IGF-1 is the main hormone responsible for the body's growth and metabolism. As a medication,
      IGF-1 is Increlex[(Trademark)] (mecasermin),

      Patients ages 2 to 20 who have not yet begun puberty, have a diagnosis of XSCID, and are
      shorter than the 3rd percentile for their age may be eligible for this study. This study will
      last about 3 years, and patients' visits will be scheduled at 3-month intervals. Patients
      will have a physical history and exam, X-rays, electrocardiogram, blood tests, and body
      measurements.

      Patients will take estradiol orally for 2 days, to help avoid false results of growth hormone
      (GH) levels in blood samples. Then provocation testing is done, with two tests back to back.
      It determines blood levels of GH and the body's response to testing with drugs called
      arginine and clonidine. Patients are admitted to the pediatric inpatient unit and will have
      an intravenous (IV) line placed in the arm. Arginine is given by IV over 30 minutes, and
      blood samples are taken. Right after arginine testing, the clonidine tablet is given. The
      IGF-1 generation test is then done to see if the body makes IGF-1 as a product in response to
      injections of GH for 5 consecutive days. This test does not require that patients are
      inpatients, but after Day 8, patients must be admitted to the pediatric unit to have blood
      sampling, start Increlex injections, and start close monitoring of blood sugar levels. They
      will learn how to do a self-injection and follow other advice. They will complete records
      about the injection site, symptoms, and side effects-keeping records for at least the first 2
      days after going home, with each dose change, and as needed. Patients stick their fingertip
      and place a small drop of blood on a blood sugar monitoring strip. The strip is put into a
      glucometer-a small hand-held device to measure the blood sugar level. Patients will be
      instructed to always have a source of sugar available in case blood sugar is too low.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2 protocol evaluating the safety and efficacy of standard dose insulin-like
      growth factor-1 (IGF-1) for the treatment of growth failure in patients diagnosed with
      X-linked severe combined immunodeficiency (XSCID). This condition is a fatal inherited
      immunodeficiency caused by defects in the common cytokine receptor gamma chain (gc), a
      subunit shared by many cytokine receptors. The common gamma subunit signals through the Janus
      kinase/signal transducers and activators of transcription (JAK/STAT) pathway, a complex
      intracellular signaling pathway used by many cytokines and growth factors, including growth
      hormone (GH). Studies have suggested that the gc defect may result in hyporesponsiveness to
      GH. This is supported by a report of GH hyporesponsiveness in an XSCID child that was
      successfully ameliorated following immune reconstitution using bone marrow transplantation
      (BMT). Haplo-identical BMTs for XSCID children often achieve only partial immune
      reconstitution, and many BMT recipients experience ongoing problems with growth failure,
      achieving heights well below 2 standard deviations for their chronological age. It is
      possible that in these partially corrected conditions, administration of IGF-1, a substance
      the body produces downstream in response to GH, may achieve an improved growth response.

      This study proposes to evaluate the safety and efficacy of Increlex(Trademark) (recombinant
      human IGF-1) for the treatment of patients with XSCID who have growth failure (children with
      heights less than 3rd percentile for age). Increlex(Trademark) is a Food and Drug
      Administration-approved drug for treatment of growth hormone non-responsiveness in the
      general population of children with growth hormone hyporesponsiveness or primary IGF-1
      deficiencies. The scientific objectives are to determine safety and to assess the efficacy of
      using subcutaneous IGF-1 in XSCID patients with growth failure. The long-term goal of this
      study is to establish improved treatment regimens for growth failure in children with XSCID.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient patient participation
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Study Drug</measure>
    <time_frame>1 year</time_frame>
    <description>Rates of adverse events related to study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Growth Rate on Study Drug</measure>
    <time_frame>During intervention, up to 2 years</time_frame>
    <description>Growth rate on intervention is compared with growth rate before intervention for each participant.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Growth Failure</condition>
  <condition>X-linked Severe Combined Immunodeficiency (XSCID)</condition>
  <condition>Growth Hormone Resistence</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Increlex</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Participants Must:

          -  Have a diagnosis of XSCID

          -  Be between 2 years to 20 years old and have not completed puberty

          -  Consent to permit blood and/or tissue samples for storage

          -  Demonstrate short stature: height below the 3 rd percentile for chronological age

          -  Have a primary care physician at home

          -  Demonstrate growth failure, defined as growth velocity (measured as linear growth)
             that is less than 5% to 10% of that expected for children of the same age group, over
             the past 12 months

          -  Willingness to remain hospitalized for several days

          -  Provide evidence of serum IGF-1 level performed within the preceding 6 months and the
             results fall below normal limits for age

        EXCLUSION CRITERIA:

        Participants Must NOT:

          -  Have fusion of epiphyseal plates

          -  Demonstrate any history of anaphylactic reaction or hypersensitivity to mecasermin or
             any component of the drug's formulation

          -  Have any active or suspected neoplasia

          -  Demonstrate signs of intracranial hypertension as evidenced by papilledema upon
             examination by fundoscopy

          -  Have any condition that, in the investigator's opinion, places the patient at undue
             risk by participating in the study

          -  Be unwilling to undergo testing or procedures associated with this protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suk S De Ravin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2007-I-0171.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Buckley RH, Schiff RI, Schiff SE, Markert ML, Williams LW, Harville TO, Roberts JL, Puck JM. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr. 1997 Mar;130(3):378-87.</citation>
    <PMID>9063412</PMID>
  </reference>
  <reference>
    <citation>Puck JM, Pepper AE, Henthorn PS, Candotti F, Isakov J, Whitwam T, Conley ME, Fischer RE, Rosenblatt HM, Small TN, Buckley RH. Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency. Blood. 1997 Mar 15;89(6):1968-77.</citation>
    <PMID>9058718</PMID>
  </reference>
  <reference>
    <citation>Leonard WJ, Shores EW, Love PE. Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development. Immunol Rev. 1995 Dec;148:97-114. Review.</citation>
    <PMID>8825284</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2007</study_first_submitted>
  <study_first_submitted_qc>June 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2007</study_first_posted>
  <results_first_submitted>March 18, 2014</results_first_submitted>
  <results_first_submitted_qc>July 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 3, 2015</results_first_posted>
  <last_update_submitted>July 2, 2015</last_update_submitted>
  <last_update_submitted_qc>July 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>X-Linked Severe Combined Immune Deficiency (XSCID)</keyword>
  <keyword>Growth Hormone</keyword>
  <keyword>Insulin-Like Growth Factor 1 (IGF)-1</keyword>
  <keyword>Bone Age</keyword>
  <keyword>Growth Failure</keyword>
  <keyword>XSCID</keyword>
  <keyword>X-Linked Severe Combined Immunodeficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>Failure to Thrive</mesh_term>
    <mesh_term>X-Linked Combined Immunodeficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Mitogens</mesh_term>
    <mesh_term>Mecasermin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Participants are young males with X-linked severe combined immunodeficiency complicated by growth failure. The participants will receive Insulin-like Growth Facor (Increlex) twice a day for up to 2 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of Study Drug</title>
        <description>Rates of adverse events related to study drug</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>XSCID patients with growth failre treated with Increlex, recombinant human IGF-1.
Increlex</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Study Drug</title>
          <description>Rates of adverse events related to study drug</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Growth Rate on Study Drug</title>
        <description>Growth rate on intervention is compared with growth rate before intervention for each participant.</description>
        <time_frame>During intervention, up to 2 years</time_frame>
        <population>Only participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Participants are young males with X-linked severe combined immunodeficiency complicated by growth failure. The participants will receive Insulin-like Growth Facor (Increlex) twice a day for up to 2 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Growth Rate on Study Drug</title>
          <description>Growth rate on intervention is compared with growth rate before intervention for each participant.</description>
          <population>Only participants who completed study</population>
          <units>cm/year</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="1.2" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea (clostridium diff)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to limited subject participation, there is insufficient complete data to generate meaningful statistics for the outcome measures. Instead, this data will be reported as a case series.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>De Ravin, SukSee</name_or_title>
      <organization>National Institute of Allergy and Infectious Diseases</organization>
      <phone>+1 301 496 6772</phone>
      <email>sderavin@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

